JPH01258622A - 動物の蛋白質と脂肪との比を増加させる方法およびその薬剤組成物 - Google Patents

動物の蛋白質と脂肪との比を増加させる方法およびその薬剤組成物

Info

Publication number: JPH01258622A
Authority: JP; Japan
Prior art keywords: cobalt; hormone; body weight; copp; mesoporphyrin
Prior art date: 1987-10-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP27943387A

Other languages

English (en)

Japanese (ja)

Other versions

JPH0525859B2 (fr

Inventor

Attallah Kappas

アタラー　カパス

George S Drummond

ジヨージ　ドラモンド

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Rockefeller University

Original Assignee

Rockefeller University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-10-13

Filing date

1987-11-06

Publication date

1989-10-16

1987-11-06 Application filed by Rockefeller University filed Critical Rockefeller University

1989-10-16 Publication of JPH01258622A publication Critical patent/JPH01258622A/ja

1993-04-14 Publication of JPH0525859B2 publication Critical patent/JPH0525859B2/ja

Status Granted legal-status Critical Current

Links

241001465754 Metazoa Species 0.000 title claims abstract description 57
238000000034 method Methods 0.000 title claims abstract description 39
239000000203 mixture Substances 0.000 title claims description 6
102000004169 proteins and genes Human genes 0.000 title abstract description 9
108090000623 proteins and genes Proteins 0.000 title abstract description 9
230000037396 body weight Effects 0.000 claims abstract description 34
238000004519 manufacturing process Methods 0.000 claims abstract description 18
AQTFKGDWFRRIHR-UHFFFAOYSA-L 3-[18-(2-carboxylatoethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoate;cobalt(2+);hydron Chemical compound [Co+2].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 AQTFKGDWFRRIHR-UHFFFAOYSA-L 0.000 claims abstract description 17
NCAJWYASAWUEBY-UHFFFAOYSA-N 3-[20-(2-carboxyethyl)-9,14-diethyl-5,10,15,19-tetramethyl-21,22,23,24-tetraazapentacyclo[16.2.1.1^{3,6}.1^{8,11}.1^{13,16}]tetracosa-1(21),2,4,6(24),7,9,11,13,15,17,19-undecaen-4-yl]propanoic acid Chemical compound N1C2=C(C)C(CC)=C1C=C(N1)C(C)=C(CC)C1=CC(C(C)=C1CCC(O)=O)=NC1=CC(C(CCC(O)=O)=C1C)=NC1=C2 NCAJWYASAWUEBY-UHFFFAOYSA-N 0.000 claims abstract description 17
229910017052 cobalt Inorganic materials 0.000 claims abstract description 17
239000010941 cobalt Substances 0.000 claims abstract description 17
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims abstract description 17
239000000745 gonadal hormone Substances 0.000 claims abstract description 10
229940088597 hormone Drugs 0.000 claims description 35
239000005556 hormone Substances 0.000 claims description 35
239000005495 thyroid hormone Substances 0.000 claims description 10
229940036555 thyroid hormone Drugs 0.000 claims description 9
229940011871 estrogen Drugs 0.000 claims description 4
239000000262 estrogen Substances 0.000 claims description 4
230000002401 inhibitory effect Effects 0.000 claims description 4
230000001105 regulatory effect Effects 0.000 claims description 4
230000004584 weight gain Effects 0.000 claims description 4
235000019786 weight gain Nutrition 0.000 claims description 4
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 3
239000003098 androgen Substances 0.000 claims description 3
230000001225 therapeutic effect Effects 0.000 claims description 2
238000007911 parenteral administration Methods 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 25
210000000750 endocrine system Anatomy 0.000 abstract description 16
230000001629 suppression Effects 0.000 abstract description 9
210000003016 hypothalamus Anatomy 0.000 abstract description 7
230000009467 reduction Effects 0.000 abstract description 5
241000283690 Bos taurus Species 0.000 abstract description 4
230000036528 appetite Effects 0.000 abstract description 4
235000019789 appetite Nutrition 0.000 abstract description 4
235000015278 beef Nutrition 0.000 abstract description 3
239000000644 isotonic solution Substances 0.000 abstract description 3
235000013305 food Nutrition 0.000 abstract description 2
235000008935 nutritious Nutrition 0.000 abstract description 2
238000009395 breeding Methods 0.000 abstract 1
230000001488 breeding effect Effects 0.000 abstract 1
206010061428 decreased appetite Diseases 0.000 abstract 1
235000020997 lean meat Nutrition 0.000 abstract 1
230000003880 negative regulation of appetite Effects 0.000 abstract 1
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 50
210000002966 serum Anatomy 0.000 description 27
229960003604 testosterone Drugs 0.000 description 25
241000700159 Rattus Species 0.000 description 15
230000007423 decrease Effects 0.000 description 10
239000000243 solution Substances 0.000 description 10
238000011282 treatment Methods 0.000 description 10
150000001875 compounds Chemical class 0.000 description 9
230000002124 endocrine Effects 0.000 description 9
206010062767 Hypophysitis Diseases 0.000 description 8
210000003635 pituitary gland Anatomy 0.000 description 8
241000124008 Mammalia Species 0.000 description 7
210000001685 thyroid gland Anatomy 0.000 description 7
241000251468 Actinopterygii Species 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
235000019688 fish Nutrition 0.000 description 6
230000002710 gonadal effect Effects 0.000 description 6
239000000122 growth hormone Substances 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
230000001228 trophic effect Effects 0.000 description 6
102000018997 Growth Hormone Human genes 0.000 description 5
108010051696 Growth Hormone Proteins 0.000 description 5
241000282412 Homo Species 0.000 description 5
108010004977 Vasopressins Proteins 0.000 description 5
102000002852 Vasopressins Human genes 0.000 description 5
230000007368 endocrine function Effects 0.000 description 5
210000003372 endocrine gland Anatomy 0.000 description 5
239000003163 gonadal steroid hormone Substances 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000000988 bone and bone Anatomy 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
230000001817 pituitary effect Effects 0.000 description 4
230000036470 plasma concentration Effects 0.000 description 4
230000028327 secretion Effects 0.000 description 4
229960003726 vasopressin Drugs 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
230000001447 compensatory effect Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
210000004907 gland Anatomy 0.000 description 3
210000002149 gonad Anatomy 0.000 description 3
150000003278 haem Chemical class 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
235000013372 meat Nutrition 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
238000012360 testing method Methods 0.000 description 3
208000016261 weight loss Diseases 0.000 description 3
230000004580 weight loss Effects 0.000 description 3
206010000599 Acromegaly Diseases 0.000 description 2
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
102000016761 Haem oxygenases Human genes 0.000 description 2
108050006318 Haem oxygenases Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
235000006439 Lemna minor Nutrition 0.000 description 2
244000242291 Lemna paucicostata Species 0.000 description 2
208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
210000004100 adrenal gland Anatomy 0.000 description 2
210000004198 anterior pituitary gland Anatomy 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
210000000845 cartilage Anatomy 0.000 description 2
235000013330 chicken meat Nutrition 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
235000013364 duck meat Nutrition 0.000 description 2
210000003811 finger Anatomy 0.000 description 2
230000036541 health Effects 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
230000002267 hypothalamic effect Effects 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000002184 metal Substances 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
230000000737 periodic effect Effects 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
210000001883 posterior pituitary gland Anatomy 0.000 description 2
244000144977 poultry Species 0.000 description 2
235000013594 poultry meat Nutrition 0.000 description 2
230000008844 regulatory mechanism Effects 0.000 description 2
239000003488 releasing hormone Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
210000001550 testis Anatomy 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
210000003371 toe Anatomy 0.000 description 2
JCLFHZLOKITRCE-UHFFFAOYSA-N 4-pentoxyphenol Chemical compound CCCCCOC1=CC=C(O)C=C1 JCLFHZLOKITRCE-UHFFFAOYSA-N 0.000 description 1
241000272525 Anas platyrhynchos Species 0.000 description 1
241000272517 Anseriformes Species 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
241000046053 Betta Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
206010013496 Disturbance in attention Diseases 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
108700012941 GNRH1 Proteins 0.000 description 1
101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
206010020850 Hyperthyroidism Diseases 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
102000009151 Luteinizing Hormone Human genes 0.000 description 1
108010073521 Luteinizing Hormone Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241001494479 Pecora Species 0.000 description 1
241000286209 Phasianidae Species 0.000 description 1
206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
241000220324 Pyrus Species 0.000 description 1
241000277331 Salmonidae Species 0.000 description 1
IDCBOTIENDVCBQ-UHFFFAOYSA-N TEPP Chemical compound CCOP(=O)(OCC)OP(=O)(OCC)OCC IDCBOTIENDVCBQ-UHFFFAOYSA-N 0.000 description 1
102000011923 Thyrotropin Human genes 0.000 description 1
108010061174 Thyrotropin Proteins 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001548 androgenic effect Effects 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000004709 eyebrow Anatomy 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
239000013505 freshwater Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
239000000960 hypophysis hormone Substances 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
210000001847 jaw Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
235000004213 low-fat Nutrition 0.000 description 1
229940040129 luteinizing hormone Drugs 0.000 description 1
238000005259 measurement Methods 0.000 description 1
210000004126 nerve fiber Anatomy 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
210000002990 parathyroid gland Anatomy 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
235000021017 pears Nutrition 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
150000004032 porphyrins Chemical class 0.000 description 1
208000006155 precocious puberty Diseases 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
201000004240 prostatic hypertrophy Diseases 0.000 description 1
230000009103 reabsorption Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
229940034208 thyroxine Drugs 0.000 description 1
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
235000014122 turkey meat Nutrition 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
239000002966 varnish Substances 0.000 description 1
230000007371 visceral function Effects 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP27943387A 1987-10-13 1987-11-06 動物の蛋白質と脂肪との比を増加させる方法およびその薬剤組成物 Granted JPH01258622A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10559187A	1987-11-13	1987-11-13
US105,591		1994-05-05

Publications (2)

Publication Number	Publication Date
JPH01258622A true JPH01258622A (ja)	1989-10-16
JPH0525859B2 JPH0525859B2 (fr)	1993-04-14

Family

ID=22306694

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP27943387A Granted JPH01258622A (ja)	1987-10-13	1987-11-06	動物の蛋白質と脂肪との比を増加させる方法およびその薬剤組成物

Country Status (1)

Country	Link
JP (1)	JPH01258622A (fr)

1987
- 1987-11-06 JP JP27943387A patent/JPH01258622A/ja active Granted

Also Published As

Publication number	Publication date
JPH0525859B2 (fr)	1993-04-14

Publication	Publication Date	Title
Millet et al.	2011	Considerations on the performance of immunocastrated male pigs
CN105878224A (zh)	2016-08-24	用于动物健康的脱落酸的组合物
JP2018504900A (ja)	2018-02-22	持続性の血漿１７−βエストラジオールレベルのための２５−ヒドロキシビタミンＤおよび抗炎症薬の組み合わせ
King et al.	1996	The effect of exogenous prolactin on lactation performance of first-litter sows given protein-deficient diets during the first pregnancy
JP2723846B2 (ja)	1998-03-09	飼料及び飼料添加物
US4948792A (en)	1990-08-14	Methods for suppressing the endocrine system
EA021832B1 (ru)	2015-09-30	Применение комбинации d-аспарагиновой и l-аспарагиновой кислот или их солей для лечения мужского бесплодия
RU1837790C (ru)	1993-08-30	Способ выращивани свиней
US5650438A (en)	1997-07-22	Process for activating reproduction in seasonal breeding animals by administering L-dihydroxyphenylalanine (L-dopa)
HU187467B (en)	1986-01-28	Method for producing preparation suitable for preventing health deterioration of alimentary origin promoting the utilization of fodder of animals
US5084475A (en)	1992-01-28	Methods for suppressing the endocrine system
AU598898B2 (en)	1990-07-05	Methods for suppressing the endocrine system
JPH01258622A (ja)	1989-10-16	動物の蛋白質と脂肪との比を増加させる方法およびその薬剤組成物
EP0217572A2 (fr)	1987-04-08	Amélioration de la qualité de carcasse
US5063223A (en)	1991-11-05	Method of controlling androstene levels in vivo with cobalt porphyrins
US5087622A (en)	1992-02-11	Method of controlling T3 and T4 levels in vivo with cobalt porphyrins
US5066650A (en)	1991-11-19	Method for suppressing the endocrine system
US6509375B1 (en)	2003-01-21	Method for increasing productivity in breeder hens
RU2166952C1 (ru)	2001-05-20	Адаптоген стресс-корректор
US3737535A (en)	1973-06-05	Method of fattening beef cattle
EP1651061B1 (fr)	2008-12-03	Complement alimentaire contenant une combinaison de cartilage et d'argent
RU2343906C2 (ru)	2009-01-20	Способ коррекции и профилактики патологических состояний животных
MXPA04006940A (es)	2004-12-06	Metodo para la estimulacion del crecimiento y resistencia a enfermedades en organismos acuaticos..
Marshall et al.	1993	Effects of growth hormone and thyroxine on kidney insulin-like growth factor-I and renal growth in hypophysectomized rats
US5053391A (en)	1991-10-01	Composition containing polypeptide hormone for stimulating skeletal growth in poultry